Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 752 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oncologic Disorders Clear all
Not listed No phase listed Observational

Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00005900
View directory record Official record
Conditions
I Cell Disease, Fucosidosis, Globoid Cell Leukodystrophy, Adrenoleukodystrophy, Mannosidosis, Niemann-Pick Disease, Pulmonary Complications, Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Metachromatic Leukodystrophy, Gaucher's Disease, Wolman Disease
Interventions
Not listed
Lead sponsor
Fairview University Medical Center
Other
Eligibility
0 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 1:23 AM EDT
Completed Not applicable Interventional

Connect Oncology Needs Evaluation Tool

NCT03919864
View directory record Official record
Conditions
Lung Cancer
Interventions
CONNECT Intervention, CONTROL Group
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 25, 2026, 1:23 AM EDT
Recruiting Not applicable Interventional

Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery

NCT06731998
View directory record Official record
Conditions
Oncologic Surgery, Cancer, Cancer Surgery, Hepatic Cancer, Gastric (Cardia, Body) Cancer, Biliary Tract Cancer, Pancreatic Cancer Resectable, Gynecologic Cancers, Gastrointestinal Cancers, Colorectal Cancer, Minimally Invasive Surgical Procedures
Interventions
Local Anesthesia, Laparoscopic Transversus Abdominis Plane block
Procedure
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 89 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 25, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease

NCT03081884
View directory record Official record
Conditions
Cancer
Interventions
FACBC PET-CT Imaging
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 25, 2026, 1:23 AM EDT
Completed Phase 1 Interventional

AMG 319 Lymphoid Malignancy FIH

NCT01300026
View directory record Official record
Conditions
Cancer, Chronic Lymphocytic Leukemia, Diffuse Large Cell Lymphoma, Hematologic Malignancies, Hematology, Leukemia, Low Grade Lymphoma, Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Oncology, Oncology Patients, T Cell Lymphoma, Tumors
Interventions
AMG 319
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Hackensack, New Jersey • Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 25, 2026, 1:23 AM EDT
Terminated Phase 2 Interventional

Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer

NCT00216216
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Pemetrexed
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
16
States / cities
Newark, Delaware • Galesburg, Illinois • Elkhart, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Oct 25, 2026, 1:23 AM EDT
Completed Phase 1 Interventional Results available

Clinical Study of WT2725 in Patients With Advanced Malignancies

NCT01621542
View directory record Official record
Conditions
Cancer
Interventions
WT2725
Biological
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
6
States / cities
Tucson, Arizona • La Jolla, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 25, 2026, 1:23 AM EDT
Terminated Phase 2 Interventional Results available

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

NCT02624388
View directory record Official record
Conditions
Lymphoma, Childhood Lymphoma, Solid Tumor, Childhood Solid Tumor, Neuroblastoma, Ewing Sarcoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Medulloblastoma, Germ Cell Tumor, Wilms Tumor, Brain Neoplasms, Medulloblastoma, Childhood, Neuroectodermal Tumors, Primitive
Interventions
Genistein, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
1 Year to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 25, 2026, 1:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer

NCT00216203
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Pemetrexed, Cetuximab
Drug
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
11
States / cities
Galesburg, Illinois • Bloomington, Indiana • Elkhart, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 25, 2026, 1:23 AM EDT
Recruiting Early Phase 1 Interventional

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

NCT06700070
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Interventions
PBA-0111
Drug
Lead sponsor
Pure Biologics S.A.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 25, 2026, 1:23 AM EDT
Completed Phase 1 Interventional

Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma

NCT00687622
View directory record Official record
Conditions
Solid Tumours
Interventions
GSK1120212
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
Scottsdale, Arizona • Aurora, Colorado • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 25, 2026, 1:23 AM EDT
Completed No phase listed Observational

Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer

NCT00876070
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Not listed
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Oct 25, 2026, 1:23 AM EDT
Completed Not applicable Interventional

A Feasibility Study of Smoking Cessation Program in Radiation Oncology

NCT00236288
View directory record Official record
Conditions
Cancer and Tobacco Abuse
Interventions
Bupropion and intensive behavioral therapy
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 31, 2007 · Synced Oct 25, 2026, 1:23 AM EDT
Completed Phase 1 Interventional

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

NCT04299880
View directory record Official record
Conditions
Oncology
Interventions
Napabucasin, Nab-paclitaxel, Gemcitabine, Nivolumab, Paclitaxel, Irinotecan, Leucovorin, 5Fluorouracil, Bevacizumab
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • Scarborough, Maine • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 25, 2026, 1:23 AM EDT
Completed Not applicable Interventional

Randomized Controlled Trial of Virtual Reality Assisted Guided Imagery (VRAGI) for Pain in Advanced Cancer Patients.

NCT05348174
View directory record Official record
Conditions
Cancer Pain, Oncology, Virtual Reality, Depression, Anxiety
Interventions
Virtual Reality Assisted Guided Imagery (VRAGI)
Behavioral
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Clemson, South Carolina • Columbia, South Carolina • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 25, 2026, 1:23 AM EDT
Recruiting No phase listed Observational

Response to Influenza Vaccination in Pediatric Oncology Patients

NCT05384288
View directory record Official record
Conditions
Hematologic Malignancy, Pediatric Cancer, Transplant-Related Cancer
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 25, 2026, 1:23 AM EDT
Recruiting No phase listed Observational

Spine Oncology Registry

NCT07225491
View directory record Official record
Conditions
Spine Tumor, Spine Metastases, Spine Cancer
Interventions
Not listed
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
5
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

NCT02141282
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 25, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas

NCT00319735
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Radiation Therapy, Surgery, Tissue Sample
Procedure
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
Galesburg, Illinois • Indianapolis, Indiana • Terre Haute, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 25, 2026, 1:23 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

PRESENCE Project: An Early Palliative Care Intervention in Brain Tumors

NCT01652768
View directory record Official record
Conditions
Malignant Brain Tumors
Interventions
Research Questionnaires, Palliative Care Team, Educational Information Session for Patients and Caregivers, Contact every 2 weeks, Follow-up Surgical Visit Session, Medical and/or Radiation Oncology Appointment Session
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Oct 25, 2026, 1:23 AM EDT
Completed Not applicable Interventional Results available

EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options

NCT03602885
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Colorectal Cancer
Interventions
Usual chemotherapy education (CE), Chemotherapy education intervention (CEI)
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Tampa, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 25, 2026, 1:23 AM EDT
Recruiting Phase 3 Interventional

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
26
States / cities
Chandler, Arizona • Fullerton, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 25, 2026, 1:23 AM EDT
Recruiting No phase listed Observational

Bone Marrow Imaging and Clinical Outcomes Across Hematologic, Oncologic, and Other Relevant Conditions

NCT07743476
View directory record Official record
Conditions
Hematologic, Oncologic, Bone Marrow
Interventions
Data Collection
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 25, 2026, 1:23 AM EDT
Terminated No phase listed Observational

Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors

NCT03391791
View directory record Official record
Conditions
Solid and Hematological Malignancies
Interventions
Genetically engineered T Cell Receptors
Genetic
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 25, 2026, 1:23 AM EDT